Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, describes which FLT3 inhibitors his group uses to treat different subsets of patients with acute myeloid leukemia (AML ). This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.